Syndax's Revuforj wins FDA approval in aggressive form of leukemia

Syndax Pharmaceuticals won the first FDA approval last week in a new class of medicines called menin inhibitors. The treatment, Revuforj, will be available as soon as this month for patients with an aggressive form ...